A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 35/14 (2006.01) A61K 38/19 (2006.01) A61P 35/00 (2006.01) A61K 39/145 (2006.01) A61K 39/29 (2006.01) A61K 39/38 (2006.01) A61K 39/385 (2006.01) C12N 5/08 (2006.01)
Patent
CA 2388221
A cancer immunotheraphy method and composition for treating cancer in a patient comprised of vaccinating a pa-tient with a vaccine comprised of the patient's own malignancy and an immunologic adjuvant, removing primed peripheral blood T lymphocytes from the patient, stimulating the primed T lymphocytes to differentiate into effector lymphocytes in vitro, stimulating the effector T lymphocytes to proliferate in vitro, and infusing the effector T lymphocytes back into the patient.
L'invention concerne une méthode d'immunothérapie anticancéreuse et une composition pour le traitement du cancer chez un patient. Ladite méthode consiste à : inoculer à un patient un vaccin comprenant les cellules malignes propres à ce dernier et un adjuvant immunologique ; à prélever sur le patient des lymphocytes T du sang périphérique ; à stimuler les lymphocytes T amorcés, de sorte que les lymphocytes T amorcés se différencient en lymphocytes T effecteurs ; à stimuler les lymphocytes T effecteurs, de manière qu'ils prolifèrent in vitro et à réintroduire par perfusion les lymphocytes T dans le patient.
Fetherstonhaugh & Co.
Tvax Biomedical Llc
Wood Gary W.
LandOfFree
Composition and method of cancer antigen immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method of cancer antigen immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method of cancer antigen immunotherapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2081729